Global Gastroparesis Drugs Market 2017-2021

  • ID: 4231694
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Cadila Pharmaceuticals
  • Evoke Pharma
  • GlaxoSmithKline
  • Johnson & Johnson
  • Theravance Biopharma
  • Valeant
  • MORE
Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.

The analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Cadila Pharmaceuticals
- GlaxoSmithKline
- Johnson & Johnson
- Valeant

Other prominent vendors
- Evoke Pharma
- Teva Pharmaceutical Industries
- Theravance Biopharma

Market drivers
- Rising cases of diabetes fueling the prevalence of diabetic gastroparesis.
- For a full, detailed list, view the full report

Market challenges
- Difficulty in diagnosis is hampering the medication process.
- For a full, detailed list, view the full report

Market trends
- Introduction of novel ways for the treatment of gastroparesis symptoms.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cadila Pharmaceuticals
  • Evoke Pharma
  • GlaxoSmithKline
  • Johnson & Johnson
  • Theravance Biopharma
  • Valeant
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: Disease overview

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by disease type
  • Diabetic gastroparesis
  • Idiopathic gastroparesis
  • Others
PART 09: Market segmentation by drug class
  • Prokinetic agents
  • Antiemetic agents
  • Botulinum toxin injection
PART 10: Geographical segmentation
  • Gastroparesis drugs market in Americas
  • Gastroparesis drugs market in EMEA
  • Gastroparesis drugs market in APAC
PART 11: Decision framework

PART 12: Drivers and challenges
  • Market drivers
  • Market challenges
PART 13: Market trends
  • Fast track approvals and acquisitions to change the phase of the market
  • Introduction of novel ways for the treatment of gastroparesis symptoms
PART 14: Vendor landscape
  • Competitive scenario
  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits

Exhibit 01: Causes of gastroparesis
Exhibit 02: Major complications associated with gastroparesis
Exhibit 03: Diagnosis and treatment of gastroparesis
Exhibit 04: Global gastroparesis drugs market snapshot
Exhibit 05: Global gastroparesis drug market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global gastroparesis drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline summary based on vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global gastroparesis drugs market by disease type 2016
Exhibit 11: Global gastroparesis drugs market share by disease type 2016 (%)
Exhibit 12: Market snapshot: Global gastroparesis drugs market 2016-2021
Exhibit 13: Function of vagus nerves in digestive system
Exhibit 14: Global diabetic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 15: Global idiopathic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 16: Other causes of gastroparesis
Exhibit 17: Global gastroparesis drugs market by other causes 2016-2021 ($ millions)
Exhibit 18: Segmentation of global gastroparesis drug market by drug class
Exhibit 19: Market analysis of gastroparesis drug class
Exhibit 20: Global gastroparesis drugs market based on geography 2016 and 2021
Exhibit 21: Global gastroparesis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Gastroparesis drugs market in the Americas 2016-2021 ($ millions)
Exhibit 24: Top American countries with diabetic population range (millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: Gastroparesis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 27: Market scenario in APAC
Exhibit 28: Top Asian countries with diabetic population range (millions)
Exhibit 29: Gastroparesis drugs market in APAC 2016-2021 ($ millions)
Exhibit 30: New cases of diabetes by 2040
Exhibit 31: Possible treatments for gastroparesis.
Exhibit 32: Alternate treatment options for gastroparesis
Exhibit 33: Factors affecting the diagnosis of gastroparesis
Exhibit 34: Strategic success factors of companies in global gastroparesis drug market
Exhibit 35: Competitive structure analysis of global gastroparesis market
Exhibit 36: Cadila Pharmaceuticals: Key highlights
Exhibit 37: Cadila Pharmaceuticals: Strength assessment
Exhibit 38: Cadila Pharmaceuticals: Strategy assessment
Exhibit 39: Cadila Pharmaceuticals: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Valeant: Key highlights
Exhibit 49: Valeant: Strength assessment
Exhibit 50: Valeant: Strategy assessment
Exhibit 51: Valeant: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Cadila Pharmaceuticals
  • Evoke Pharma
  • GlaxoSmithKline
  • Johnson & Johnson
  • Theravance Biopharma
  • Valeant
  • MORE
New Report Released: - Global Gastroparesis Drugs Market 2017-2021.

The author of the report recognizes the following companies as the key players in the global gastroparesis drugs market: Cadila Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, and Valeant.

Other Prominent Vendors in the market are: Evoke Pharma, Teva Pharmaceutical Industries, and Theravance Biopharma.

Commenting on the report, an analyst from the research team said: “One trend in market is fast track approvals and acquisitions to change the phase of the market. High unmet needs in the treatment of gastroparesis have led the fast track approvals of certain drugs. For example, in 2016, Theravance Biopharma received the US FDA fast track designation for velusetrag for idiopathic and diabetic gastroparesis. At present, the drug is in Phase II clinical stage. The fast track approval by the US FDA is done to facilitate the need to treat serious conditions associated with gastroparesis.”

According to the report, one driver in market is rising gastric surgeries fueling the prevalence rate of post-surgical gastroparesis. Post-surgical gastroparesis is the third most common type of the gastroparesis after idiopathic and diabetic gastroparesis. Gastric surgeries include surgeries that are done to digestive parts of the bodies such as the esophagus, duodenum, and stomach. During the gastric surgery, there is a high chance that the vagus nerves get injured. Injury to these nerves is the major cause of gastroparesis. Some of the common types of gastric surgeries are gastric bypass surgeries and bariatric surgeries. Rising obesity is a major reason for these surgeries. As one of the major aims of these surgeries is weight loss. Vagus nerve damage is one of the major complications associated with gastric bypass. Sleeve gastrectomy has also seen to alter the gut-brain communication.

Further, the report states that one challenges in market is weak pipeline for gastroparesis. The weak pipeline of gastroparesis is a huge challenge for the gastroparesis drugs market. At present Metozolv ODT (metoclopramide hydrochloride) is the only US FDA-approved drug used for the treatment of diabetic gastroparesis. The situation is even worse for idiopathic gastroparesis, which does not have any US FDA-approved drug for its treatment. Even though there are very limited options available for the treatment of gastroparesis, the pipeline is quite thin. Most of the drugs currently in the pipeline focus on diabetic gastroparesis, which suggests that idiopathic gastroparesis is still an un-addressed segment of the market. The R&D process for idiopathic gastroparesis becomes even more difficult because of lack of knowledge regarding the actual cause of the disease. Current drug development for gastroparesis lags behind many other pharmaceutical developments. This restricts the growth of gastroparesis market. Also, termination of clinical trials is expected to hamper the market growth. For instance, GlaxoSmithKline and Adolor received a letter of approval for a New Drug Application (NDA) for alvimopan, a new drug for the treatment of IBS, slow transit constipation, and gastroparesis. However, it was later suspended due to long-term safety concerns.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant
  • Evoke Pharma
  • Teva Pharmaceutical Industries
  • Theravance Biopharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll